CN113056456B - Tyk2激酶抑制剂 - Google Patents

Tyk2激酶抑制剂 Download PDF

Info

Publication number
CN113056456B
CN113056456B CN201980066166.4A CN201980066166A CN113056456B CN 113056456 B CN113056456 B CN 113056456B CN 201980066166 A CN201980066166 A CN 201980066166A CN 113056456 B CN113056456 B CN 113056456B
Authority
CN
China
Prior art keywords
compound
tyk2
compounds
disease
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980066166.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113056456A (zh
Inventor
J·C·里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of CN113056456A publication Critical patent/CN113056456A/zh
Application granted granted Critical
Publication of CN113056456B publication Critical patent/CN113056456B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980066166.4A 2018-10-08 2019-10-07 Tyk2激酶抑制剂 Active CN113056456B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
GB1816369.1 2018-10-08
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
CN113056456A CN113056456A (zh) 2021-06-29
CN113056456B true CN113056456B (zh) 2023-06-13

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066166.4A Active CN113056456B (zh) 2018-10-08 2019-10-07 Tyk2激酶抑制剂

Country Status (18)

Country Link
US (1) US12187716B2 (https=)
EP (1) EP3864009B1 (https=)
JP (1) JP7383030B2 (https=)
KR (1) KR102844196B1 (https=)
CN (1) CN113056456B (https=)
AU (1) AU2019359320B2 (https=)
BR (1) BR112021006424A2 (https=)
CA (1) CA3111049A1 (https=)
DK (1) DK3864009T3 (https=)
ES (1) ES3021420T3 (https=)
FI (1) FI3864009T3 (https=)
GB (1) GB201816369D0 (https=)
IL (1) IL281599B2 (https=)
MX (1) MX2021003929A (https=)
PL (1) PL3864009T3 (https=)
PT (1) PT3864009T (https=)
SG (1) SG11202102490TA (https=)
WO (1) WO2020074461A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796038A (zh) * 2007-05-10 2010-08-04 萨勒姆有限公司 *唑酪氨酸激酶抑制剂
EP2634185A1 (en) * 2012-03-02 2013-09-04 Sareum Limited TYK2 kinase inhibitors
CN105793245A (zh) * 2013-09-03 2016-07-20 萨勒姆有限公司 药物化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
ATE394102T1 (de) 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
CN100400040C (zh) 2000-10-30 2008-07-09 詹森药业有限公司 三肽酶抑制剂
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
ES2395581T3 (es) 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
WO2009155156A1 (en) 2008-06-18 2009-12-23 Merck & Co., Inc. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2793024A1 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20140228349A1 (en) 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796038A (zh) * 2007-05-10 2010-08-04 萨勒姆有限公司 *唑酪氨酸激酶抑制剂
EP2634185A1 (en) * 2012-03-02 2013-09-04 Sareum Limited TYK2 kinase inhibitors
CN105793245A (zh) * 2013-09-03 2016-07-20 萨勒姆有限公司 药物化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
选择性氮杂吲哚类JAK抑制剂的设计、合成及体外活性评价;常先磊;中国人民解放军军事医学科学院硕士学位论文;全文 *

Also Published As

Publication number Publication date
BR112021006424A2 (pt) 2021-07-06
AU2019359320B2 (en) 2024-04-04
DK3864009T3 (da) 2025-03-17
EP3864009A1 (en) 2021-08-18
JP7383030B2 (ja) 2023-11-17
KR102844196B1 (ko) 2025-08-07
US12187716B2 (en) 2025-01-07
US20210387981A1 (en) 2021-12-16
IL281599B1 (en) 2024-06-01
ES3021420T3 (en) 2025-05-26
PT3864009T (pt) 2025-04-23
FI3864009T3 (fi) 2025-03-24
GB201816369D0 (en) 2018-11-28
IL281599A (en) 2021-05-31
CA3111049A1 (en) 2020-04-16
PL3864009T3 (pl) 2025-04-22
SG11202102490TA (en) 2021-04-29
WO2020074461A1 (en) 2020-04-16
KR20210076036A (ko) 2021-06-23
EP3864009B1 (en) 2025-02-19
MX2021003929A (es) 2021-06-04
CN113056456A (zh) 2021-06-29
AU2019359320A1 (en) 2021-03-18
JP2022514799A (ja) 2022-02-15
IL281599B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
US11673870B2 (en) Pharmaceutical compounds
JP6239118B2 (ja) 医薬化合物
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
CN113056456B (zh) Tyk2激酶抑制剂
JP7660135B2 (ja) Ｔｙｋ２阻害剤の結晶形態
RU2805932C2 (ru) Фармацевтические соединения
HK40048146B (en) Tyk2 kinase inhibitors
HK40048146A (en) Tyk2 kinase inhibitors
HK1226067B (zh) 药物化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant